Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220505 | 0.86 | KDM4E (0.47) | L3MBTL1SMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL30880789 | 0.86 | KDM4E (0.47) | L3MBTL1SMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL13291240 | 0.83 | PLCG1 (0.51) | L3MBTL1POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12145500 | 0.81 | L3MBTL1 (0.49) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL4717654 | 0.81 | USP2 (0.48) | POLBSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL22552075 | 0.77 | PDE5A (0.43) | KDM4EALDH1A1PLCG1 | |
| SCHEMBL9390976 | 0.77 | SMN1; SMN2 (0.55) | L3MBTL1POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10221817 | 0.76 | PKM (0.49) | ALDH1A1PLCG1HSD17B10ALOX15 | |
| SCHEMBL27858859 | 0.76 | CYP11B1 (0.40) | PLCG1 | |
| SCHEMBL28263826 | 0.76 | CYP11B1 (0.40) | SMN1; SMN2PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | L3MBTL1 3595/4885POLB 3282/4885SMN1; SMN2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.